Europe Non-Invasive Prenatal Testing Market: Global Size, Share, Trends, Growth and Forecast, 2022-2032
Europe Non-Invasive Prenatal Testing Market Overview
Non-invasive prenatal testing (NIPT) is a type of prenatal genetic testing that is performed on maternal blood to detect certain chromosomal abnormalities in the fetus. The test is non-invasive and poses no risk to the fetus. The Europe non-invasive prenatal testing market is the market for these testing services in the European region.
The Europe non-invasive prenatal testing market has been growing rapidly in recent years, driven by factors such as increasing awareness of NIPT, rising maternal age, and increasing incidence of chromosomal abnormalities. The market is also influenced by the growing adoption of NIPT by healthcare providers and patients due to its accuracy, non-invasiveness, and reduced risk of miscarriage.
The Europe non-invasive prenatal testing market can be segmented based on test type, end user, and geography. The test type segment includes screening and diagnostic tests. The end user segment includes hospitals, diagnostic laboratories, and research laboratories. Geographically, the market can be segmented into Western Europe and Eastern Europe.
The key players in the Europe non-invasive prenatal testing market include Illumina, Inc., BGI Group, Natera, Inc., Roche Holding AG, and Thermo Fisher Scientific, Inc. These companies offer a range of products and services for NIPT, including screening and diagnostic tests, test kits, and laboratory services.
The Europe non-invasive prenatal testing market is highly competitive, with several large and small players offering a range of products and services. The market is characterized by the presence of several established players as well as new entrants.
In summary, the Europe non-invasive prenatal testing market refers to the market for non-invasive prenatal genetic testing services in the European region. The market is growing rapidly and is driven by factors such as increasing awareness of NIPT, rising maternal age, and increasing incidence of chromosomal abnormalities. The market is highly competitive, with several large and small players offering a range of products and services.
The Europe non-invasive prenatal testing market size was estimated at USD 0.51 billion in 2019 and is expected grow with a CAGR of 18.4% over the forecasted period of 2021 to 2032. The Europe market growth is significantly pushed by the need for non-invasive prenatal tests (NIPT) in clinical routine to determine fetal aneuploidies from maternal blood.
Some factors may fuel the innovation and connectors market. They are, high occurrence rate of babies born with Down syndrome, major shift in trend towards childbearing at elder maternal age (35 years or older), and no risk of miscarriage with NIPT test.
The business will present promising development possibilities, which are stemmed by the blend of various factors. Some of these factors are, increased awareness of NIPT in the Europe and surge in reimbursement scenario for NIPT.
Noninvasive prenatal testing (NIPT) method determines the risk of the fetus being born with certain genetic abnormalities. It investigates minor fragments of DNA circulating in a pregnant woman's blood. Surge in a number of pregnancy during elder maternal age in Europe offers lucrative opportunities for the market growth. For example, as per the Office for National Statistics, the average age of first-time mothers in England increased from 27.9 years in 2011 to 28.8 years in 2017.
The Europe market is seeing extensive consolidations, launches, and acquisitions. These are embraced by the key players of the market to increase their geographical presence and product portfolio. For example, in April 2017, Illumina, the U.S.-based next-generation sequencing (NGS) giant launched NGS-based non-invasive prenatal test (NIPT) in Europe. This launch in Europe enables rapid testing of the fetal chromosome status by using a single maternal blood draw.
Blood diagnosis of Down syndrome has become an important for routine prenatal checkup in several European Union (EU) countries, especially Germany, UK, and France. This factor is fortifying the Europe non-invasive prenatal test market. The UK area may surface as a main district over the estimated time frame. The provincial market development may be due to the support of United Kingdom National Health Service, the UK's publicly funded healthcare systems.
The volume of NIPT tests is increasing at rapid pace in UK and Germany due to greater involvement of health agency as well as technology assessment organizations. However, in Spain, noticeably increased number of women with miscarriages with invasive methods drives the market's growth. On the other hand, rise in awareness & education concerning genetic testing and earliest testing for Down’s syndrome in Italy pushes growth of the market.
The reimbursement scenario in European countries is one of the major factor fueling growth of the market. For example, French National Health System compensates about $481.03 to pregnant women for screening and prenatal diagnosis.
In view of product types, the market has been portioned into instruments, and consumables & reagents. The consumables & reagents section is the biggest portion, regarding income, and may rule the innovation field, as far as size, by 2025.
The instruments section is projected to observe highest development rates, due to the ongoing collaborations among the market players to introduce cost effective & highly sensitive instruments to detect trisomy during pregnancy. For instance, QIAGEN, a German provider of sample and assay technologies partnered with Natera, Inc. a developer of next-generation sequencing (NGS) assays to develop innovative cell-free DNA assays for the usage on QIAGEN’s GeneReader NGS System.
To accomplish cutting-edge innovation licenses, consolidation and acquisitions have advanced as a significant piece of the current non-invasive prenatal test industry. For example, Eurofins Scientific, the European leader in non-invasive prenatal testing (NIPT) signed an agreement with Noritsu Koki Co., Ltd. to acquire GeneTech Inc., a leading player in genetic analysis & NIPT in Japan.
End User Insights
In light of utilizations, the market is divided into hospitals and clinical laboratories. The hospitals fragment is the biggest section and will overwhelm the end user field, by 2025. The clinical laboratories section would observe a significant growth during the forecast period.
In comparison with hospitals, clinical laboratories are more equipped with several advanced technologies to ensure effective and safe prenatal tests regarding chromosomal abnormalities. In addition to this, the clinical laboratories in Europe are considerably adopting advanced strategies to strengthen non-invasive prenatal testing (NIPT) capabilities.
For example, Loratoire CERBA, the European reference laboratory specialized in clinical pathology signed an agreement with SeraCare Life Sciences, a global partner of in vitro diagnostics manufacturers & clinical laboratories to provide custom Seraseq Aneuploidy Reference Materials to use with Laboratoire CERBA's non-invasive prenatal testing (NIPT) assay.
Competitive Market Insights
The key business members of the market are ILLUMINA, NATERA, Ariosa Diagnostics (Roche), LifeCodexx AG, Premaitha Health PLC, NIPD Genetics, and Lab Corp. (SEQUENOME). The broad acknowledgment of the web has affected expanded selection of NIPT in the global hospitals and clinical laboratories.